{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:30:46Z","timestamp":1790314246891,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00980-6","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:51:19Z","timestamp":1782741079000},"page":"2167-2180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Steroid-Sparing Effect of Efgartigimod in Generalized Myasthenia Gravis: Study Protocol for a Single-Arm, Open-Label Clinical Trial"],"prefix":"10.1007","volume":"15","author":[{"given":"Tetsu","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6766-5145","authenticated-orcid":false,"given":"Motoki","family":"Fujimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Ohuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shioya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"980_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol. 2024;20:84\u201398. https:\/\/doi.org\/10.1038\/s41582-023-00916-w.","journal-title":"Nat Rev Neurol"},{"key":"980_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013278","volume":"7","author":"Y Nagane","year":"2017","unstructured":"Nagane Y, Murai H, Imai T, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7:e013278. https:\/\/doi.org\/10.1136\/bmjopen-2016-013278.","journal-title":"BMJ Open"},{"key":"980_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141\u20139. https:\/\/doi.org\/10.1002\/mus.20950.","journal-title":"Muscle Nerve"},{"key":"980_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1586\/14737175.9.3.351","volume":"9","author":"NE Gilhus","year":"2009","unstructured":"Gilhus NE. Autoimmune myasthenia gravis. Expert Rev Neurother. 2009;9:351\u20138. https:\/\/doi.org\/10.1586\/14737175.9.3.351.","journal-title":"Expert Rev Neurother"},{"key":"980_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000365892","volume":"65","author":"XX Liu","year":"2014","unstructured":"Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65:324\u201332. https:\/\/doi.org\/10.1159\/000365892.","journal-title":"Ann Nutr Metab"},{"key":"980_CR6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ard.2008.092163","volume":"68","author":"D Huscher","year":"2009","unstructured":"Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68:1119\u201324. https:\/\/doi.org\/10.1136\/ard.2008.092163.","journal-title":"Ann Rheum Dis"},{"key":"980_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020;16:437\u201347. https:\/\/doi.org\/10.1038\/s41574-020-0341-0.","journal-title":"Nat Rev Endocrinol"},{"key":"980_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/mus.24213","volume":"50","author":"K Utsugisawa","year":"2014","unstructured":"Utsugisawa K, Suzuki S, Nagane Y, et al. Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle Nerve. 2014;50:493\u2013500. https:\/\/doi.org\/10.1002\/mus.24213.","journal-title":"Muscle Nerve"},{"key":"980_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000322497","volume":"65","author":"Y Nagane","year":"2011","unstructured":"Nagane Y, Suzuki S, Suzuki N, Utsugisawa K. Early aggressive treatment strategy against myasthenia gravis. Eur Neurol. 2011;65:16\u201322. https:\/\/doi.org\/10.1159\/000322497.","journal-title":"Eur Neurol"},{"key":"980_CR10","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/mus.25397","volume":"55","author":"K Utsugisawa","year":"2017","unstructured":"Utsugisawa K, Nagane Y, Akaishi T, et al. Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve. 2017;55:794\u2013801. https:\/\/doi.org\/10.1002\/mus.25397.","journal-title":"Muscle Nerve"},{"key":"980_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki III","year":"2000","unstructured":"Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Neurology. 2000;55:16\u201323. https:\/\/doi.org\/10.1212\/WNL.55.1.16.","journal-title":"Neurology"},{"key":"980_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13544","volume":"1413","author":"H Murai","year":"2018","unstructured":"Murai H, Utsugisawa K, Nagane Y, Suzuki S, Imai T, Motomura M. Rationale for the clinical guidelines for myasthenia gravis in Japan. Ann N Y Acad Sci. 2018;1413:35\u201340. https:\/\/doi.org\/10.1111\/nyas.13544.","journal-title":"Ann N Y Acad Sci"},{"key":"980_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","volume":"94","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Suzuki S, Kuwabara S, et al. Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2023;94:467\u201373. https:\/\/doi.org\/10.1136\/jnnp-2022-330519.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"980_CR14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715\u201325. https:\/\/doi.org\/10.1038\/nri2155.","journal-title":"Nat Rev Immunol"},{"key":"980_CR15","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Investig. 2018;128:4372\u201386. https:\/\/doi.org\/10.1172\/JCI97911.","journal-title":"J Clin Investig"},{"key":"980_CR16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2021;20:526\u201336. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9.","journal-title":"Lancet Neurol"},{"key":"980_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/mus.28334","volume":"71","author":"NJ Silvestri","year":"2025","unstructured":"Silvestri NJ. Individualized dosing of efgartigimod in patients with generalized myasthenia gravis: clinical experience at a single center. Muscle Nerve. 2025;71:422\u20138. https:\/\/doi.org\/10.1002\/mus.28334.","journal-title":"Muscle Nerve"},{"key":"980_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251319656","author":"L Jin","year":"2025","unstructured":"Jin L, Zou Z, Wang Q, et al. Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes. Ther Adv Neurol Disord. 2025. https:\/\/doi.org\/10.1177\/17562864251319656.","journal-title":"Ther Adv Neurol Disord"},{"key":"980_CR19","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52:1487\u20139. https:\/\/doi.org\/10.1212\/WNL.52.7.1487.","journal-title":"Neurology"},{"key":"980_CR20","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns TM, Conaway M, Sanders DB. The MG Composite: a valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74:1434\u201340. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1b1e.","journal-title":"Neurology"},{"key":"980_CR21","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","volume":"54","author":"TM Burns","year":"2016","unstructured":"Burns TM, Sadjadi R, Utsugisawa K, et al. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016;54:1015\u201322. https:\/\/doi.org\/10.1002\/mus.25198.","journal-title":"Muscle Nerve"},{"key":"980_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.556104","volume":"11","author":"RJ Nowak","year":"2020","unstructured":"Nowak RJ, Muppidi S, Beydoun SR, O\u2019Brien FL, Yountz M, Howard JFJ. Concomitant immunosuppressive therapy use in eculizumab-treated adults with generalized myasthenia gravis during the REGAIN open-label extension study. Front Neurol. 2020;11, 556104. https:\/\/doi.org\/10.3389\/fneur.2020.556104.","journal-title":"Front Neurol"},{"key":"980_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/cpj.0000000000200276","volume":"14","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Uzawa A, Nagane Y, et al. Therapeutic responses to efgartigimod for generalized myasthenia gravis in Japan. Neurol Clin Pract. 2024;14:e200276. https:\/\/doi.org\/10.1212\/cpj.0000000000200276.","journal-title":"Neurology Clinical Practice"},{"key":"980_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham MC, Masi G, Patzina R, et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 2023;146:319\u201336. https:\/\/doi.org\/10.1007\/s00401-023-02603-y.","journal-title":"Acta Neuropathol"},{"key":"980_CR25","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200436","volume":"12","author":"F Khani-Habibabadi","year":"2025","unstructured":"Khani-Habibabadi F, Roy B, Pham MC, et al. AChR autoantibody pathogenic properties are heterogeneously distributed and undergo temporal changes among patients with myasthenia gravis. Neurol Neuroimmunol Neuroinflamm. 2025;12:e200436. https:\/\/doi.org\/10.1212\/nxi.0000000000200436.","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00980-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00980-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00980-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:37Z","timestamp":1784819497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00980-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["980"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00980-6","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Motoki Fujimaki has received research funding from argenx BV to support the conduct of this investigator-initiated clinical trial. Tetsu Suzuki declares that he has no competing interests. Shogo Ohuchi declares that he has no competing interests. Takashi Hosaka declares that he has no competing interests. Ayako Shioya declares that she has no competing interests. Shinji Saiki has received research funding from argenx BV in connection with this investigator-initiated clinical trial.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the Clinical Research Review Board, University of Tsukuba, Japan (Approval No. CRB3180028). The trial was prospectively registered with the Japan Registry of Clinical Trials (jRCT, CRB3180028) on 1 October 2024. The study will be conducted in accordance with the Declaration of Helsinki of 1964 and its later amendments, and with relevant institutional and national ethical and regulatory guidelines. All participants will be fully informed about the study procedures, potential risks, and benefits prior to enrollment, and written informed consent will be obtained from every participant before any study procedure. Participants will be free to withdraw from the study at any time without penalty or impact on their ongoing medical care. No identifying information of individual participants is included in this manuscript.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}